Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
IVERMECTIN vs ALBENDAZOLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ivermectin is a macrocyclic lactone that binds selectively and with high affinity to glutamate-gated chloride ion channels in invertebrate nerve and muscle cells, leading to increased chloride ion influx, hyperpolarization, and paralysis of the parasite. It also interacts with other ligand-gated chloride channels, such as those gated by gamma-aminobutyric acid (GABA). In mammals, these channels are largely confined to the central nervous system, but ivermectin does not readily cross the blood-brain barrier, providing a safety margin.
Albendazole inhibits tubulin polymerization by binding to beta-tubulin, disrupting microtubule formation, which leads to impaired glucose uptake and depletion of glycogen stores in susceptible parasites, resulting in their immobilization and death.
FDA-approved: Treatment of onchocerciasis (river blindness), strongyloidiasis, and intestinal infections caused by Strongyloides stercoralis.,FDA-approved: Scabies (topical formulation).,Off-label: Treatment of other parasitic infections including ascariasis, trichuriasis, enterobiasis, filariasis, loiasis, and cutaneous larva migrans.,Off-label: Treatment of severe, refractory, or crusted scabies (oral).,Off-label: Used in combination with albendazole for lymphatic filariasis.,Investigational: Used for scabies in institutional settings and for rosacea (topical).
Cystic hydatid disease (Echinococcus granulosus),Neurocysticercosis (Taenia solium),Giardiasis (off-label),Cutaneous larva migrans (off-label),Trichuriasis (off-label),Ascariasis (off-label),Hookworm infections (off-label)
150–200 mcg/kg orally once, with repeat dose in 2 weeks for strongyloidiasis; for scabies, 200 mcg/kg orally once, repeat in 2 weeks if needed.
400 mg orally twice daily for 3-7 days for most indications; for neurocysticercosis, 400 mg orally twice daily for 8-30 days; for hydatid disease, 400 mg orally twice daily for 28-day cycles with 14-day drug-free intervals for 3 cycles.
Terminal elimination half-life is approximately 18 hours (range 12-24 hours) in healthy adults; prolonged in hepatic impairment.
Terminal half-life of albendazole sulfoxide is 8–12 hours; parent drug half-life is <1 hour. Clinical context: supports once- or twice-daily dosing.
Ivermectin is primarily metabolized in the liver by the cytochrome P450 enzyme CYP3A4. It is also a substrate of P-glycoprotein (P-gp).
Primarily hepatic via microsomal enzymes; undergoes oxidation to albendazole sulfoxide (active metabolite) by CYP3A4 and flavin-containing monooxygenases (FMO). Further metabolized to albendazole sulfone (inactive) and other oxidative metabolites.
Primarily fecal (≥90% as unchanged drug and metabolites); renal excretion is minimal (<1% of dose). Biliary excretion contributes to fecal elimination.
Primarily renal (80%) as inactive metabolites; <2% unchanged in urine. Biliary/fecal excretion accounts for ~20%.
Approximately 93% bound to plasma proteins, primarily albumin and possibly alpha-1-acid glycoprotein.
70% bound to plasma proteins, primarily albumin.
Apparent volume of distribution is 3.1-3.5 L/kg (large, indicating extensive tissue distribution including fat and skin).
0.2–0.6 L/kg, indicating distribution into tissues; concentrates in liver, bile, and cerebrospinal fluid.
Oral bioavailability is approximately 60-80% (due to extensive first-pass metabolism). Topical bioavailability is negligible (<1% systemic absorption).
Oral bioavailability is low (~5%) due to extensive first-pass metabolism; co-administration with a high-fat meal increases bioavailability up to 4–5-fold.
No dose adjustment required for any degree of renal impairment.
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (Cr Cl <15 m L/min), use with caution; consider dose reduction or extended intervals. No specific GFR-based guidelines available.
Use with caution in severe hepatic impairment; specific Child-Pugh-based dosing not established.
Contraindicated in patients with severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), use with caution; monitor liver function. No specific dose adjustment guidelines available.
Weight-based: 150–200 mcg/kg orally once, same as adult; safety for children weighing less than 15 kg not established.
For children >2 years: 15 mg/kg/day orally in 2 divided doses (max 800 mg/day) for most indications. For neurocysticercosis: 15 mg/kg/day orally in 2 divided doses (max 800 mg/day) for 8-30 days. For hydatid disease: 15 mg/kg/day orally in 2 divided doses (max 800 mg/day) for 28-day cycles with 14-day drug-free intervals. For children <2 years: safety and efficacy not established.
No specific dose adjustment; monitor for adverse effects due to potential age-related organ dysfunction.
No specific dose adjustment recommended; use with caution due to potential age-related hepatic or renal impairment. Monitor liver function and blood counts regularly.
No FDA black box warnings.
Albendazole may cause fetal harm when administered to pregnant women. It is contraindicated in pregnancy and should not be used in women who are or may become pregnant. Women of childbearing potential should have a negative pregnancy test before starting treatment and should use effective contraception during therapy and for one month after completion.
Severe skin reactions (Mazzotti reaction) when treating onchocerciasis, including pruritus, urticaria, fever, arthralgias, syncope, and lymphadenitis.,Neurological toxicity in high doses or with compromised blood-brain barrier (e.g., due to meningitis, African trypanosomiasis, or Loa loa infection with high microfilarial loads).,Ocular reactions in onchocerciasis: exacerbation of eye lesions, including optic neuritis and chorioretinitis.,Potential for drug interactions with CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) or P-gp inhibitors (e.g., verapamil, cyclosporine), leading to increased ivermectin exposure.,Hypersensitivity reactions.,Use in pregnancy only if clearly needed (data limited).,Not recommended in children under 5 years of age or weighing less than 15 kg.
Bone marrow suppression: Monitor CBC at start and periodically; risk of pancytopenia, particularly in patients with hepatic disease or receiving high doses.,Hepatotoxicity: Monitor liver function tests due to risk of elevated transaminases and rare hepatic failure.,Risk of neurocysticercosis exacerbation: May cause increased intracranial pressure or seizures; treat with corticosteroids and anticonvulsants as needed.,Retinal damage: In ocular neurocysticercosis, evaluate for retinal lesions before therapy due to risk of retinal damage from inflammation.,Renal impairment: Use with caution; dose adjustment may be necessary.,Lactation: Excreted in breast milk; caution in nursing mothers.
Hypersensitivity to ivermectin or any component of the formulation.,Concurrent use with drugs that inhibit CYP3A4 or P-gp may require caution, but absolute contraindication is rare.,Loa loa infection with high microfilarial loads (risk of severe encephalopathy).
Pregnancy (absolute),Known hypersensitivity to albendazole or any of its components,Patients with pre-existing bone marrow suppression (relative)
Ivermectin should be taken on an empty stomach with water. Administration with food, particularly high-fat meals, can significantly increase absorption (up to 2.5-fold), potentially increasing the risk of adverse effects. Therefore, avoid food for at least 2 hours before and 1 hour after dosing. Grapefruit juice may inhibit CYP3A4 and could theoretically increase ivermectin levels; caution is advised.
Take with a high-fat meal (≥40 g fat) to significantly increase oral bioavailability. Avoid grapefruit juice as it may affect drug metabolism. No specific dietary restrictions otherwise.
FDA Category C. Animal studies show teratogenicity at high doses. Human data limited; avoid in first trimester unless benefit outweighs risk. No increased malformation risk in second/third trimester from observational studies.
FDA Category C. First trimester: risk of skeletal abnormalities and embryotoxicity based on animal studies. Second and third trimesters: limited human data, but potential for fetal harm; avoid use unless benefit outweighs risk.
Ivermectin is excreted into breast milk; M/P ratio unknown. Limited human data suggests low levels. Caution in infants weighing <15 kg due to potential CNS effects. Consider temporary cessation of breastfeeding during therapy.
Excreted in breast milk; M/P ratio not established. Use with caution, especially in neonates due to risk of bone marrow suppression.
Pharmacokinetics in pregnancy not well studied. No recommended dose adjustments. Use standard weight-based dosing (150–200 mcg/kg) but avoid in first trimester unless essential.
No specific dose adjustment recommended in pregnancy; pharmacokinetic changes not well studied. Use lowest effective dose and shortest duration possible.
Ivermectin is a broad-spectrum antiparasitic agent that causes parasite death by increasing chloride ion conductance in invertebrate nerve and muscle cells. It is the drug of choice for onchocerciasis and strongyloidiasis, and is also used for scabies and head lice. For onchocerciasis, it is given as a single dose of 150 mcg/kg, repeated every 6-12 months. For strongyloidiasis, the recommended dose is 200 mcg/kg daily for 2 days. For crusted scabies, multiple doses (e.g., on days 1, 2, 8, 9) may be required. Note: Ivermectin does not kill adult Onchocerca worms but reduces microfilarial load. Severe adverse effects (Mazzotti reaction) can occur in onchocerciasis due to rapid microfilarial killing. Avoid in patients with Loa loa co-infection due to risk of encephalopathy. Ivermectin is not recommended for children under 15 kg or pregnant women unless benefits outweigh risks. Drug interactions: caution with CYP3A4 inhibitors or inducers; consider dose adjustment with strong inhibitors like ketoconazole.
Albendazole is a broad-spectrum anthelmintic that inhibits microtubule polymerization by binding to beta-tubulin. It is highly effective against Echinococcus granulosus cysts but requires prolonged therapy (e.g., 28-day cycles). Monitor liver function tests (LFTs) at baseline and every 2 weeks due to risk of hepatotoxicity. For neurocysticercosis, co-administer corticosteroids to reduce inflammatory reaction from cyst degeneration. Albendazole is pregnancy category C; avoid in first trimester and in women planning pregnancy within 1 month of therapy. Absorption is enhanced by a fatty meal; administer with a high-fat meal to increase bioavailability up to 5-fold.
Take ivermectin exactly as prescribed, usually on an empty stomach with water.,For strongyloidiasis or scabies, you may need a second dose; complete the full course.,Do not take with food, especially high-fat meals, as they may increase absorption and risk of side effects.,Common side effects include dizziness, pruritus, and gastrointestinal upset.,Report any severe skin rash, swelling, or difficulty breathing immediately.,If being treated for onchocerciasis, you may experience a reaction (fever, itching, joint pain) due to dying parasites; this is usually mild and treatable.,Avoid driving or operating machinery if you experience dizziness or drowsiness.,Inform your doctor if you are pregnant, breastfeeding, or taking other medications.,Do not use ivermectin for COVID-19; it is not approved for viral infections.
Take this medication with a fatty meal (e.g., eggs, avocado, nuts) to improve absorption.,Do not crush or chew the tablets; swallow them whole with water.,Complete the full course of therapy even if you feel better.,Report any signs of liver problems: yellowing of skin/eyes, dark urine, severe nausea, or abdominal pain.,Avoid pregnancy during treatment and for at least 1 month after the last dose; use reliable contraception.,You may experience dizziness or blurred vision; avoid driving or operating machinery until you know how the drug affects you.,If you are breastfeeding, discuss with your doctor before taking this medication.
"Coadministration of ivermectin, a known inhibitor of cytochrome P450 3A4 (CYP3A4), with netupitant, a CYP3A4 substrate, can result in increased systemic exposure to netupitant. This may potentiate netupitant-related adverse effects, such as nausea, fatigue, and QT prolongation, particularly in patients with underlying hepatic impairment or those receiving other QT-prolonging agents."
"Ivermectin is a substrate of CYP3A4 and P-glycoprotein (P-gp), while imatinib is primarily metabolized by CYP3A4 and is also a substrate of P-gp. Concomitant administration of ivermectin may competitively inhibit CYP3A4 and P-gp, reducing the clearance of imatinib and increasing its systemic exposure. This can potentiate imatinib's adverse effects, including hepatotoxicity, fluid retention, and myelosuppression, particularly at high doses."
"Ivermectin is a moderate inhibitor of CYP3A4, the primary enzyme responsible for simeprevir metabolism. Concomitant administration significantly reduces simeprevir clearance, leading to elevated plasma concentrations. This increases the risk of simeprevir-related adverse effects, including hepatotoxicity, QT prolongation, and rash."
"Albendazole inhibits the CYP3A4-mediated metabolism of clemastine, leading to increased plasma concentrations of clemastine. This can potentiate the anticholinergic and sedative effects of clemastine, including dry mouth, urinary retention, constipation, and drowsiness. Patients may experience heightened central nervous system depression, especially with concurrent use of other CNS depressants."
"Ranolazine, a piperazine derivative antianginal agent, is a moderate CYP3A4 inhibitor. Albendazole is primarily metabolized by CYP3A4 to its active metabolite, albendazole sulfoxide. Coadministration increases albendazole systemic exposure by approximately 50%, potentially enhancing both therapeutic efficacy and dose-dependent toxicities, including hepatotoxicity and bone marrow suppression."
"Albendazole inhibits CYP3A4, the enzyme primarily responsible for the metabolism of lovastatin. This inhibition reduces lovastatin clearance, leading to elevated plasma concentrations and increased risk of statin-related adverse effects such as myopathy, rhabdomyolysis, and hepatotoxicity. Patients receiving this combination should be monitored closely for signs of muscle pain or weakness and liver enzyme abnormalities."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about IVERMECTIN vs ALBENDAZOLE, answered by our medical review team.
IVERMECTIN is a Anthelmintic that works by Ivermectin is a macrocyclic lactone that binds selectively and with high affinity to glutamate-gated chloride ion channels in invertebrate nerve and muscle cells, leading to increased chloride ion influx, hyperpolarization, and paralysis of the parasite. It also interacts with other ligand-gated chloride channels, such as those gated by gamma-aminobutyric acid (GABA). In mammals, these channels are largely confined to the central nervous system, but ivermectin does not readily cross the blood-brain barrier, providing a safety margin.. ALBENDAZOLE is a Anthelmintic that works by Albendazole inhibits tubulin polymerization by binding to beta-tubulin, disrupting microtubule formation, which leads to impaired glucose uptake and depletion of glycogen stores in susceptible parasites, resulting in their immobilization and death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between IVERMECTIN and ALBENDAZOLE depend on the specific clinical indication. These are both Anthelmintic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of IVERMECTIN is: 150–200 mcg/kg orally once, with repeat dose in 2 weeks for strongyloidiasis; for scabies, 200 mcg/kg orally once, repeat in 2 weeks if needed.. The standard adult dose of ALBENDAZOLE is: 400 mg orally twice daily for 3-7 days for most indications; for neurocysticercosis, 400 mg orally twice daily for 8-30 days; for hydatid disease, 400 mg orally twice daily for 28-day cycles with 14-day drug-free intervals for 3 cycles.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between IVERMECTIN and ALBENDAZOLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. IVERMECTIN is classified as Category A/B. FDA Category C. Animal studies show teratogenicity at high doses. Human data limited; avoid in first trimester unless benefit outweighs risk. No increased malformation risk in seco. ALBENDAZOLE is classified as Category D/X. FDA Category C. First trimester: risk of skeletal abnormalities and embryotoxicity based on animal studies. Second and third trimesters: limited human data, but potential for fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.